Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06477640 · ClinicalTrials.gov registry record · NA

Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension

A NA study of Pulmonary Arterial Hypertension PAH, sponsored by University of Rochester.

Recruiting
Registry status
NA
Development phase
55
Enrollment target
1
Study location

NCT06477640 is a NA study of Pulmonary Arterial Hypertension PAH that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 55 participants, above the 37-participant average among 5 other Pulmonary Arterial Hypertension PAH trials with a reported enrollment target (49% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06477640, a NA study of Pulmonary Arterial Hypertension PAH, is actively recruiting participants, sponsored by University of Rochester.

RECRUITING
Registry status
NA
Development phase
55 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate whether a home rehabilitation program for patients diagnosed with Pulmonary Arterial Hypertension (PAH) will decrease Cardiac Effort (number of heart beats used during 6-minute walk test/walk distance) and improve quality of life. Ultimately, this information could help improve the management of patients with PAH.

Interventions

  • BEHAVIORAL Exercise
  • BEHAVIORAL Standard of Care

Study Locations (1)

New York

  • University of Rochester Medical Center - Rochester

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2024-07-29
Est. Completion 2026-12-31
Phase NA

Sponsor

University of Rochester

636 total trials

What the Registry Record Tells You About NCT06477640

The ClinicalTrials.gov registry entry for NCT06477640 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 37-participant average among 5 other Pulmonary Arterial Hypertension PAH trials with a reported enrollment target (49% higher). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pulmonary Arterial Hypertension PAH appearing as the primary indexed condition, and to 2 interventions - of which Exercise is the first listed.

NCT06477640 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06477640 about?

NCT06477640 is a clinical study titled "Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension". The purpose of this study is to evaluate whether a home rehabilitation program for patients diagnosed with Pulmonary Arterial Hypertension (PAH) will decrease Cardiac Effort (number of heart beats used during 6-minute walk test/walk distance) and improve quality of life. Ultimately, this information...

What is the current status of trial NCT06477640?

This trial is currently recruiting. It is a NA study. The enrollment target is 55 participants. The study started on 2024-07-29. Estimated completion is 2026-12-31.

What conditions does trial NCT06477640 study?

This clinical trial studies the following conditions: Pulmonary Arterial Hypertension PAH.

What interventions are being tested in trial NCT06477640?

The interventions under investigation include: Exercise (BEHAVIORAL), Standard of Care (BEHAVIORAL).

Who is sponsoring clinical trial NCT06477640?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06477640 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pulmonary Arterial Hypertension PAH

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.